U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C12H17N2O3.Na
Molecular Weight 260.2647
Optical Activity ( + / - )
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SECOBARBITAL SODIUM

SMILES

[Na+].CCCC(C)C1(CC=C)C(=O)NC(=O)[N-]C1=O

InChI

InChIKey=AXXJTNXVUHVOJW-UHFFFAOYSA-M
InChI=1S/C12H18N2O3.Na/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16;/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C12H18N2O3
Molecular Weight 238.2829
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/seconal-sodium-drug.htm http://www.wikidoc.org/index.php/Secobarbital_sodium https://www.glowm.com/resources/glowm/cd/pages/drugs/s004.html

Secobarbital sodium, a barbiturate, is FDA approved for the treatment of insomnia and for pre-anesthetic use. This drug binds at a distinct site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. Adverse reactions are drowsiness, lethargy, hangover, paradoxical excitement in elderly patients, somnolence. Rifampin may decrease secobarbital levels by increasing metabolism.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SECONAL SODIUM

Approved Use

A.Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see Clinical Pharmacology). B.Preanesthetic

Launch Date

4.33987191E11
Preventing
SECONAL SODIUM

Approved Use

A.Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see Clinical Pharmacology). B.Preanesthetic

Launch Date

4.16102416E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2 μg/mL
5 mg/kg single, rectal
dose: 5 mg/kg
route of administration: Rectal
experiment type: SINGLE
co-administered:
SECOBARBITAL plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
20.2 μg × h/mL
5 mg/kg single, rectal
dose: 5 mg/kg
route of administration: Rectal
experiment type: SINGLE
co-administered:
SECOBARBITAL plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.9 h
5 mg/kg single, rectal
dose: 5 mg/kg
route of administration: Rectal
experiment type: SINGLE
co-administered:
SECOBARBITAL plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
16.5 mg single, intraarterial (mean)
Recommended
Dose: 16.5 mg
Route: intraarterial
Route: single
Dose: 16.5 mg
Sources:
unhealthy, adult
n = 43
Health Status: unhealthy
Condition: neurological disorders
Age Group: adult
Sex: unknown
Population Size: 43
Sources:
Other AEs: Scintillating scotoma, Epileptic fit...
Other AEs:
Scintillating scotoma (1 patient)
Epileptic fit (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Epileptic fit 1 patient
16.5 mg single, intraarterial (mean)
Recommended
Dose: 16.5 mg
Route: intraarterial
Route: single
Dose: 16.5 mg
Sources:
unhealthy, adult
n = 43
Health Status: unhealthy
Condition: neurological disorders
Age Group: adult
Sex: unknown
Population Size: 43
Sources:
Scintillating scotoma 1 patient
16.5 mg single, intraarterial (mean)
Recommended
Dose: 16.5 mg
Route: intraarterial
Route: single
Dose: 16.5 mg
Sources:
unhealthy, adult
n = 43
Health Status: unhealthy
Condition: neurological disorders
Age Group: adult
Sex: unknown
Population Size: 43
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​
PubMed

PubMed

TitleDatePubMed
Volkmann's ischemic contracture after intra-arterial injection of secobarbital.
1970 Apr 20
Pharmacological comparison of R(+), S(-) and racemic secobarbital in mice.
1970 Mar
Toxic nephropathy after low-dose methoxyflurane anesthesia: drug interaction with secobarbital?
1976 Feb 21
Seven cases of somnambulism induced by drugs.
1979 Jul
Reflex sympathetic dystrophy associated with antiepileptic drugs.
1994 Mar-Apr
Physician-assisted suicide: a review of the literature concerning practical and clinical implications for UK doctors.
2006 Jun 22
Ligand diversity of human and chimpanzee CYP3A4: activation of human CYP3A4 by lithocholic acid results from positive selection.
2009 Jun
Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening.
2011 Feb
Patents

Sample Use Guides

As a hypnotic, 100 mg at bedtime. Preoperatively, 200 to 300 mg 1 to 2 hours before surgery.
Route of Administration: Other
In Vitro Use Guide
Early studies revealed that 0.2 mM secobarbital caused a maximum decrease in cytochrome P450, requiring NADPH or an NADPH-generating system.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:57:47 UTC 2023
Edited
by admin
on Wed Jul 05 23:57:47 UTC 2023
Record UNII
XBP604F6UM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SECOBARBITAL SODIUM
GREEN BOOK   JAN   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
Common Name English
QUINALBARBITONE SODIUM
Common Name English
SECOBARBITAL SODIUM [VANDF]
Common Name English
2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5-(1-METHYLBUTYL)-5-(2-PROPENYL)-, MONOSODIUM SALT
Common Name English
SEBAR
Brand Name English
SECOBARBITAL SODIUM [USP IMPURITY]
Common Name English
BARBOSEC
Brand Name English
SECOBARBITAL SODIUM [USP MONOGRAPH]
Common Name English
SECOBARBITAL SODIUM [MART.]
Common Name English
SECOBARBITAL SODIUM [JAN]
Common Name English
EVRONAL SODIUM
Brand Name English
PRAMIL
Brand Name English
IMMENOCTAL
Brand Name English
SECOBARBITAL SODIUM [GREEN BOOK]
Common Name English
2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5-(1-METHYLBUTYL)-5-(2-PROPEN-1-YL)-, SODIUM SALT (1:1)
Systematic Name English
SECOBARBITAL SODIUM [MI]
Common Name English
Secobarbital sodium [WHO-DD]
Common Name English
SYNATE
Brand Name English
(RS)-SECOBARBITAL SODIUM
Common Name English
NSC-10818
Code English
5-ALLYL-5-(1-METHYLBUTYL)BARBITURIC ACID SODIUM SALT
Common Name English
SECOBARBITAL SODIUM [ORANGE BOOK]
Common Name English
BARBITURIC ACID, 5-ALLYL-5-(1-METHYLBUTYL)-, SODIUM SALT
Common Name English
Classification Tree Code System Code
DEA NO. 2315
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
CFR 21 CFR 522.900
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
NCI_THESAURUS C67084
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
Code System Code Type Description
CAS
51165-35-6
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
SUPERSEDED
DAILYMED
XBP604F6UM
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
PRIMARY
NCI_THESAURUS
C66530
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
PRIMARY
PUBCHEM
14148199
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
PRIMARY
MERCK INDEX
M9827
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
PRIMARY Merck Index
FDA UNII
XBP604F6UM
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
PRIMARY
EPA CompTox
DTXSID5022019
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
PRIMARY
ChEMBL
CHEMBL447
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
PRIMARY
NSC
10818
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
PRIMARY
CAS
4847-61-4
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
SUPERSEDED
ECHA (EC/EINECS)
206-218-4
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
PRIMARY
SMS_ID
100000084947
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
PRIMARY
EVMPD
SUB04344MIG
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
PRIMARY
RXCUI
91110
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
PRIMARY RxNorm
DRUG BANK
DBSALT000255
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
PRIMARY
CAS
309-43-3
Created by admin on Wed Jul 05 23:57:47 UTC 2023 , Edited by admin on Wed Jul 05 23:57:47 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY